A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus by Ilson David H, Kelsen David, Shah Manish, Schwartz Gary, Levine Douglas A, Boyd Jeff, Capanu Marinela, Miron Benjamin, Klimstra David in Cancer (2011).

[PMID: 21425140] PubMed


Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) have activity in solid tumors. The authors evaluated an oral EGFR TKI, erlotinib, in patients with previously treated esophageal cancer.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.